Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3120790
Max Phase: Preclinical
Molecular Formula: C29H31N6O8P
Molecular Weight: 622.58
Molecule Type: Small molecule
Associated Items:
ID: ALA3120790
Max Phase: Preclinical
Molecular Formula: C29H31N6O8P
Molecular Weight: 622.58
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@H](NP(=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@](C)(O)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1
Standard InChI: InChI=1S/C29H31N6O8P/c1-19(27(37)40-15-20-9-5-3-6-10-20)34-44(39,43-21-11-7-4-8-12-21)41-16-23-25(36)28(2,38)29(17-30,42-23)24-14-13-22-26(31)32-18-33-35(22)24/h3-14,18-19,23,25,36,38H,15-16H2,1-2H3,(H,34,39)(H2,31,32,33)/t19-,23+,25+,28+,29-,44?/m0/s1
Standard InChI Key: DTGIRBDEUUOOOE-ZLPYKPOHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 622.58 | Molecular Weight (Monoisotopic): 622.1941 | AlogP: 2.47 | #Rotatable Bonds: 11 |
Polar Surface Area: 203.55 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.23 | CX Basic pKa: 0.65 | CX LogP: 1.88 | CX LogD: 1.88 |
Aromatic Rings: 4 | Heavy Atoms: 44 | QED Weighted: 0.14 | Np Likeness Score: -0.02 |
1. Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, Clarke M, Doerffler E, Byun D, Wang T, Babusis D, Carey AC, German P, Sauer D, Zhong W, Rossi S, Fenaux M, McHutchison JG, Perry J, Feng J, Ray AS, Kim CU.. (2014) Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients., 57 (5): [PMID:23547794] [10.1021/jm400201a] |
Source(1):